The U.S. health insurance sector was bracing for severe margin compression amid surging post-pandemic medical costs for older adults. The Trump administration intervened heavily late Monday. The Centers for Medicare & Medicaid Services (CMS) finalized a highly favorable 5.06% to 5.1% benchmark rate increase for Medicare Advantage plans for the coming year. This policy pivot injects more than $25 billion in additional payments directly to private health insurers.
The finalized rate completely overrules the much flatter 2.2% increase proposed by the Biden administration earlier in the year. Industry giants heavily exposed to the Medicare market saw immediate reactions. Humana shares rocketed 16% in aftermarket trading. UNH stock experienced similar heavy volume. The move fundamentally alters the trajectory of the healthcare business heading into the next fiscal cycle. This influx of capital follows intense industry lobbying, according to a detailed report published Monday.
Insurers warned regulators earlier this year that without a significant reimbursement hike to catch up to actual cost growth, they would be forced to cut patient benefits, slash drug coverage, or exit regional markets entirely. Regulators responded by increasing the effective growth rate metric to upwards of 9% in the final notice. This cements the 5.1% bump as the largest Medicare Advantage rate increase in the past decade.
CMS also finalized a massive regulatory shift by overhauling the Medicare Advantage Star Ratings system. Regulators rolled back recent Biden-era initiatives and explicitly eliminated the health equity index. They reinstated an older, more generous bonus structure. This specific policy shift is expected to funnel an additional $13 billion to $18 billion in taxpayer-funded quality bonuses to insurers over the next decade. Companies like UnitedHealth Group, CVS Health, and Elevance Health stand to absorb the bulk of these restored payouts.
How the Star Ratings Reversal Alters Insurer Profitability
The immediate stock surges for Humana and UNH reflect a massive paradigm shift in federal reimbursement strategy. The Biden administration previously attempted to tightly control private insurance profits by linking bonus payments to strict health equity metrics. Monday’s ruling abandons that framework entirely.
By eliminating the health equity index and restoring the legacy bonus structure, CMS is effectively guaranteeing an additional $13 billion to $18 billion revenue stream for major providers through 2036. This is the largest regulatory financial injection the sector has seen in ten years. Insurers are now heavily incentivized to expand their regional footprints rather than scaling back operations, completely reversing the market contraction fears that dominated Wall Street earnings calls earlier this spring.